Saraton kasalligini erta tashxislash uchun innovatsion texnologiyalarni ishlab chiqishga qaratilgan tibbiy texnologiya kompaniyasi bugun yangi tadqiqot natijalarini e'lon qildi. Jigar saratonining klinik tadqiqi gepatotsellyulyar karsinomani (HCC) aniqlash uchun LAMning yangi DNK metilatsiyasiga asoslangan biomarkerining katta salohiyatini ko'rsatdi.
Ushbu tadqiqotda 130 ta sub'ektning zaxira namunalari to'plangan, jumladan: gepatotsellyulyar karsinoma tashxisi qo'yilgan 60 ta sub'ekt (I dan IV bosqichgacha), jigar kasalligi bo'lmagan 30 ta sub'ekt, 10 ta yaxshi jigar kasalligi tashxisi qo'yilgan va 30 ta ko'krak saratoni, yo'g'on ichak saratoni bilan kasallangan. yoki o'pka saratoni. Namunadan DNK olindi, DNK bisulfit bilan o'zgartirildi va IvyGene platformasi yordamida DNK metilatsiyasi miqdori aniqlandi. Barcha namunalarni ma'lumotlarni to'plash va tahlil qilishni tugatgandan so'ng, sinov samaradorligini hisoblash uchun namunalarni ko'r qiling.
A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of kolorektal saraton samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.
